Design and biological characterization of glioblastoma-effective senotherapeutics acting through Michael addition
Public support
Provider
Czech Science Foundation
Programme
Standard projects
Call for proposals
SGA0202600001
Main participants
Ústav molekulární genetiky AV ČR, v. v. i.
Contest type
VS - Public tender
Contract ID
26-21040S
Alternative language
Project name in Czech
Design and biological characterization of glioblastoma-effective senotherapeutics acting through Michael addition
Annotation in Czech
The presence of senescent cells in glioblastoma (GB) is an adverse prognostic marker. Adjuvant senolytic therapy is one of the new, intensively investigated approaches for cancer treatment. In our previous work, we prepared and characterized a new compound, methoxybenzylaminobenzothiophene dioxide (K2071), which exhibits STAT3 inhibitory, antimitotic, anti-migratory, anti-invasive, and senotherapeutic properties. We hypothesize that the mechanism of action of K2071 involves covalent binding to an as-yet unidentified molecular target(s) via a thia-Michael addition. Our pilot findings suggest that further derivatization of K2071 can separate its antimitotic and senotherapeutic effects. In this proposal, we aim to develop novel GB-effective K2071 derivatives with enhanced senolytic and senomorphic properties. Using 2D and 3D in vitro culture models of human GB cell lines, we intend to elucidate their mechanisms of action, potential resistance, and synergies with other senolytics.
Scientific branches
R&D category
ZV - Basic research
OECD FORD - main branch
30204 - Oncology
OECD FORD - secondary branch
30107 - Medicinal chemistry
OECD FORD - another secondary branch
30104 - Pharmacology and pharmacy
CEP - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
FD - Oncology and haematology<br>FP - Other medical fields<br>FR - Pharmacology and apothecary chemistry
Solution timeline
Realization period - beginning
Jan 1, 2026
Realization period - end
Dec 31, 2028
Project status
Z - Beginning multi-year project
Latest support payment
—
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP26-GA0-GA-R
Data delivery date
May 26, 2026
Finance
Total approved costs
12,633 thou. CZK
Public financial support
12,633 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK